Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Pharmacol Res. 2022 Mar 5;178:106162. doi: 10.1016/j.phrs.2022.106162

Figure 3. Targeting the ATR/CHK1/WEE1 pathway overcomes PARP inhibitor resistance.

Figure 3.

Monotherapy or combination therapies with ATR/CHK1/WEE1 inhibitors overcome PARP inhibitor resistance by disrupting both HR and replication fork protection, leading to accumulation of DNA damage throughout the cell cycle and increased cell death.